Article

Collaboration: Pfizer, Eyetech in deal for AMD, DME therapy

New York-Pfizer Inc. and Eyetech Pharmaceuticals Inc. will jointly develop and commercialize Eyetech's pegaptanib sodium (Macugen) as a potential treatment for age-related macular degeneration (AMD) and diabetic macular edema (DME).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
Related Content
FDA approves prednisolone acetate ophthalmic suspension for treating steroid-responsive ocular inflammation
June 12th 2025

FDA approves prednisolone acetate ophthalmic suspension for treating steroid-responsive ocular inflammation

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Formosa Pharmaceuticals grants Harrow US commercial rights to clobetasol propionate ophthalmic suspension 0.05% (BYQLOVI), terminates deal with Eyenovia
June 12th 2025

Formosa Pharmaceuticals grants Harrow US commercial rights to clobetasol propionate ophthalmic suspension 0.05% (BYQLOVI), terminates deal with Eyenovia

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Zeteo Biomedical secures US and EU patents for drug delivery technologies
June 12th 2025

Zeteo Biomedical secures US and EU patents for drug delivery technologies

NIH study identifies brain circuits critical to visual acuity beyond the retina
June 12th 2025

NIH study identifies brain circuits critical to visual acuity beyond the retina

© 2025 MJH Life Sciences

All rights reserved.